Play Live Radio
Next Up:
0:00
0:00
Available On Air Stations
The Conversation

FDA approves emergency use for first rapid COVID-19 test developed in Hawaiʻi

ASSURE-100-Dexter-scaled.jpeg
Courtesy Oceanit
/

The Food and Drug Administration has approved emergency use of the first rapid COVID-19 test developed by a Hawaiʻi company.

Patrick Sullivan, president and CEO of Oceanit, says the company began working on a saliva spit test but switched to a shallow nasal swab for easier use.

ASSURE-100 was developed using artificial intelligence and is manufactured in South Korea.

Sullivan says the FDA approval is validation after a long tough road.

"This is the first of many things we plan to do. We created a platform technology," Sullivan said. "We originally set out to look at diseases like cancer, we have a toolset for that. So our goal is really to address those issues."

"But when the pandemic hit, we asked ourselves, what can we do to help make a difference and a rapid test is what we came up with, and took us a while to get there. Hawaiʻi doesn't have a lot of the infrastructure but we were determined to do it," he said.

Sullivan applauded his team for bringing the breakthrough science to market.

Oceanit said its ASSURE-100 rapid antigen test for COVID-19 produces results in minutes.

This interview aired on The Conversation on March 1, 2022. The Conversation airs weekdays at 11 a.m. on HPR-1.

Related Content